Novo Nordisk Plunges 20% YTD: How Should Investors Play the Stock?

Key Takeaways Novo Nordisk stock is down 19.9% YTD due to weak obesity study data and regulatory headwinds. NVO faces stiff competition from Lilly's blockbuster GLP-1 drugs, including Zepbound and Mounjaro. Wegovy sales rose 83% in Q1 2025 and NVO is expanding semaglutide indications and manufacturing capacity.Novo Nordisk (NVO) shares have plunged 19.9% year to date, following a string of unfavorable outcomes, both pipeline and regulatory, that have led investors to bet against the company. The company r ...